Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796170 · ClinicalTrials.gov registry record · Phase 4
Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes
A Phase 4 study of Hypertension and Type 2 Diabetes, sponsored by Tulane University School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT02796170 is a Phase 4 study of Hypertension and Type 2 Diabetes that has completed, run by Tulane University School of Medicine. The registered enrollment target is 11 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02796170, a Phase 4 study of Hypertension and Type 2 Diabetes, has completed, sponsored by Tulane University School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for 6 weeks. In addition there will be an arm of 10 subjects who will receive sulfonylurea in an open label as a comparative to the cross over subjects to assess if the effect of Dapagliflozin may also be in part due to improved glycemic control.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin
Study Locations (1)
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796170
The ClinicalTrials.gov registry entry for NCT02796170 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The listed sponsor is Tulane University School of Medicine, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02796170 reports 1 study location spanning 1 distinct geographic area - top geographies include Louisiana.
Frequently Asked Questions
What is clinical trial NCT02796170 about?
NCT02796170 is a clinical study titled "Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes". To assess the effect of sodium-glucose cotransporter 2 (SGLT-2) inhibitors on blood pressure and urinary angiotensinogen. This is a cross over study design, where 40 subjects will receive Dapagliflozin for 6 weeks followed by placebo for 6 weeks, or placebo for 6 weeks followed by Dapagliflozin for ...
What is the current status of trial NCT02796170?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2016-03. Estimated completion is 2020-08.
What conditions does trial NCT02796170 study?
This clinical trial studies the following conditions: Hypertension, Type 2 Diabetes.
What interventions are being tested in trial NCT02796170?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02796170?
This trial is sponsored by Tulane University School of Medicine, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02796170 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Aspirin After Preeclampsia: TAP Trial
RECRUITING · Phase 4
-
Impact GLP-1 Agonists Following Bariatric
RECRUITING · Phase 4
-
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
RECRUITING · Phase 4
-
Bridging the Evidence-to-practice Gap
RECRUITING · Phase 4
-
Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension
RECRUITING · Phase 4
-
Secondhand Tobacco Smoke and Cardiovascular Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.